Targeted drug trial aims to shrink inoperable thyroid tumors before surgery
NCT ID NCT01709292
Summary
This study is testing if a drug called vemurafenib can shrink thyroid tumors before surgery in patients with advanced cancer. The drug targets a specific genetic mutation found in the cancer cells. Researchers will measure changes in tumor size and certain biomarkers after 56 days of treatment to see if the drug is effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.